Randomized trial demonstrates enhanced drug delivery and wound healing with chondroitin sulfate and chondroitinase ABC, suggesting promising therapeutic applications.
Chondroitin sulfate (CS), a naturally occurring glycosaminoglycan, is renowned for its biocompatibility, biodegradability, and considerable role in wound healing and drug delivery applications. In wound healing, CS fosters tissue regeneration by augmenting cell signaling, extracellular matrix remodeling, and accelerating tissue repair. As a drug delivery system, CS acts as an adaptable carrier, improving stability, bioavailability, and controlled release of therapeutic agents. Its ability to form hydrogels and nanoparticles enables prolonged, site-specific drug delivery, ensuring targeted therapeutic action at injury sites. Recent advancements have focused on CS-based formulations for chronic wound treatment, emphasizing its role in tissue regeneration and faster healing. The integration of CS with biomaterials like collagen and hydroxyapatite further optimizes therapeutic outcomes. In addition to CS, chondroitinase ABC (chABC) has gained attention for its potential in wound healing and drug delivery. chABC, an enzyme that degrades chondroitin sulfate chains, promotes tissue repair by breaking down inhibitory extracellular matrix components and promoting cell migration. The combination of CS and chABC could offer synergistic effects, enhancing wound healing and drug delivery efficiency. Challenges remain in optimizing formulations for clinical use, including stability, scalability, and regulatory issues, but the future potential for CS and chABC in therapy is significant.
No takes yet. Share an insight, caveat, or question.
Abualsoud et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: